Boston Scientific (BSX) 10-K Summary — Year Ended Dec 31, 2024
Boston Scientific Corporation filed its annual report with the SEC. The filing provides limited extracted context, but includes revenue growth and ongoing litigation exposure.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Boston Scientific Corporation filed its annual report with the SEC. The filing provides limited extracted context, but includes revenue growth and ongoing litigation exposure.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$16.7B
Revenue reported for the fiscal year.
Operating income
$2.6B
Income from operations reported for the year.
Net income
$1.8B
Net income reported for the year.
Operating cash flow
$3.4B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11.9B | n/a |
| Dec 31, 2022 | $12.7B | +6.7% |
| Dec 31, 2023 | $14.2B | +12.3% |
| Dec 31, 2024 | $16.7B | +17.6% |
Business overview
The supplied filing context does not contain a detailed description of the company's business operations. Only a table of contents referencing the business overview section is provided.
Financial performance
Revenue has increased over recent periods. For the most recent reporting period, the company reported operating income, net income, and operating cash flow.
Material risks
The company faces potential material losses from ongoing litigation and claims, which could adversely affect operations. Restructuring activities also present execution risks.
Liquidity and capital
The company has allocated capital to restructuring initiatives and litigation-related matters. No broader liquidity or capital allocation themes are discussed in the supplied context.
What to watch
The resolution of outstanding litigation and the progress of the restructuring plan.